Adma Biologics, Inc.
ADMA· Nasdaq
Released Nov 5, 2020, after the close
10-Q filed Nov 5, 2020, 36 days after period end · 0001193805-20-001392
| Metric | Q3 2020 | Q3 2019 | Q3 2018 | Q3 2017 |
|---|---|---|---|---|
| Revenue | $10.28M | $7.22M | $4.23M | $4.73M |
| Net Income | -$16.92M | -$11.44M | -$15.14M | -$15.20M |
| EPS Diluted |
Adma Biologics, Inc. · CIK 1368514 · Engraved from SEC EDGAR
| -$0.19 |
| -$0.19 |
| -$0.33 |
| -$0.59 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.